Angiotensin II Receptor Blockers in Pregnancy: A Case Report and Systematic Review of the Literature

REFERENCES

• American College of Obstetricians and Gynecologists. Technical bulletin No. 219. Hypertension in pregnancy. Int J Gynecol Obstet 1996; 53: 175–183
   PubMed Web of Science ®Google Scholar
• Sibai BM. Chronic hypertension in pregnancy. Obstet Gynecol 2002; 100: 369–377
   PubMed Web of Science ®Google Scholar
• Daikha-Dahmane F, Levy-Beff E, Jugie M, Lenclen R. Foetal kidney maldevelopment in maternal use of angiotensin II type I receptor antagonists. Pediatr Nephrol 2006; 21: 729–732
   Google Scholar
• Boix E, Zapater P, Pico A, Moreno O. Teratogenicity with angiotensin II receptor antagonists in pregnancy. J Endocrinol Invest 2005; 28: 1029–1031
   PubMed Web of Science ®Google Scholar
• Vendemmia M, Garcia-Meric P, Rizzotti A, Boubred F, Lacroze V, Liprandi A, Simeoni U. Fetal and neonatal consequences of antenatal exposure to type 1 angiotensin II receptor-antagonists. J Matern Fetal Neonatal Med 2005; 18: 137–140
   PubMed Web of Science ®Google Scholar
• Bos-Thompson MA, Hillaire-Buys D, Muller F, Dechaud H, Mazurier E, Boulot P, Morin D. Fetal toxic effects of angiotensin II receptor antagonists: case report and follow-up after birth. Ann Pharmacother 2005; 39: 157–161
   PubMed Web of Science ®Google Scholar
• Philipp T, Philipp K, Reiner A, Beer F, Kalousek DK. Embryoscopic and cytogenetic analysis of 233 missed abortions: factors involved in the pathogenesis of developmental defects of early failed pregnancies. Hum Reprod 2003; 18: 1724–1732
   PubMed Web of Science ®Google Scholar
• Moore KL, Persaud TVN. The Developing Human: Clinically Oriented Embryology6 th. W.B. Saunders Inc, Philadelphia, PA 1998
   Google Scholar
• Bald M, Holder M, Zieger M, Vochem M, Leichter HE. Increased renal echogenicity in a preterm neonate. Kidneys with tubular dysplasia due to exposure to candesartan during pregnancy. Pediatr Nephrol 2005; 20: 1664–1668
   PubMedGoogle Scholar
• Berkane N, Carlier P, Verstraete L, Mathieu E, Heim N, Uzan S. Fetal toxicity of valsartan and possible reversible adverse side effects. Birth Defects Res A Clin Mol Teratol 2004; 70: 547–549
   PubMedGoogle Scholar
• Nayar B, Singhal A, Aggarwal R, Malhotra N. Losartan induced fetal toxicity. Indian J Pediatr 2003; 70: 923–924
   PubMedGoogle Scholar
• Schaefer C. Angiotensin II-receptor-antagonists: further evidence of fetotoxicity but not teratogenicity. Birth Defects Res A Clin Mol Teratol 2003; 67: 591–594
   PubMedGoogle Scholar
• Cox RM, Anderson JM, Cox P. Defective embryogenesis with angiotensin II receptor antagonists in pregnancy. BJOG 2003; 110: 1038
   PubMedGoogle Scholar
• Pietrement C, Malot L, Santerne B, Roussel B, Motte J, Morville P. Neonatal acute renal failure secondary to maternal exposure to telmisartan, angiotensin II receptor antagonist. J Perinatol 2003; 23: 254–255
   PubMedGoogle Scholar
• Biswas PN, Wilton LV, Shakir SW. The safety of valsartan: results of a postmarketing surveillance study on 12881 patients in England. J Hum Hypertens 2002; 16: 795–803
   PubMed Web of Science ®Google Scholar
• Briggs GG, Nageotte MP. Fatal fetal outcome with the combined use of valsartan and atenolol. Ann Pharmacother 2001; 35: 859–861
   PubMed Web of Science ®Google Scholar
• Martinovic J, Benachi A, Laurent N, Daikha-Dahmane F, Gubler MC. Fetal toxic effects and angiotensin-II-receptor antagonists. Lancet 2001; 358: 241–242
   PubMed Web of Science ®Google Scholar
• Lambot MA, Vermeylen D, Noel JC. Angiotensin-II-receptor inhibitors in pregnancy. Lancet 2001; 357: 1619–1620
   PubMed Web of Science ®Google Scholar
• Hinsberger A, Wingen AM, Hoyer PF. Angiotensin-II-receptor inhibitors in pregnancy. Lancet 2001; 357: 1620
   PubMedGoogle Scholar
• Chung NA, Lip GY, Beevers M, Beevers DG. Angiotensin-II-receptor inhibitors in pregnancy. Lancet 2001; 357: 1620–1621
   PubMedGoogle Scholar
• Saji H, Yamanaka M, Hagiwara A, Ijiri R. Losartan and fetal toxic effects. Lancet 2001; 357: 363
   PubMed Web of Science ®Google Scholar
• Mann R, Mackay F, Pearce G, Freemantle S, Wilton L. Losartan: a study of pharmacovigilance data on 14,522 patients. J Hum Hypertens 1999; 13: 551–557
   PubMed Web of Science ®Google Scholar
• Khan KS, Wojdyla D, Say L, Gulmezoglu AM, van Look PF. WHO analysis of causes of maternal death: a systematic review. Lancet 2006; 367: 1066–1074
   PubMed Web of Science ®Google Scholar
• He J, Gu D, Wu X, Reynolds K, Duan X, Yao C, Yao C, Wang J, Chen CS, Chen J, Wildman RP, Klag MJ, Whelton PK. Major causes of death among men and women in China. N Engl J Med 2005; 353: 1124–1134
   PubMed Web of Science ®Google Scholar
• Frishman WH, Schlocker SJ, Awad K, Tejani N. Pathophysiology and medical management of systemic hypertension in pregnancy. Cardiol Rev 2005; 13: 274–284
   PubMedGoogle Scholar
• Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde R, Raz I, Collaborative Study Group. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345: 851–860
   PubMed Web of Science ®Google Scholar
• Weber MA, Julius S, Kjeldsen SE, Brunner HR, Ekman S, Hansson L, Hua T, Laragh JH, McInnes GT, Mitchell L, Plat F, Schork MA, Smith B, Zanchetti A. Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial. Lancet 2004; 363: 2049–2051
   PubMed Web of Science ®Google Scholar
• Casas JP, Chua W, Loukogeorgakis S, Vallance P, Smeeth L, Hingorani AD, MacAllister RJ. Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis. Lancet 2005; 366: 2026–2033
   PubMed Web of Science ®Google Scholar
• Barr M. Teratogen update: angiotensin-converting enzyme inhibitors. Teratology 1994; 50: 399–409
   PubMedGoogle Scholar